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(Background) There is a close link between fungal sensitization and asthma severity. 
Though Schizophillum commune (S. commune, called“suehirotake”in Japanese), one of 
the basidiomycetous (BM) fungi, is a fungus that can cause allergic bronchopulmonary 
mycosis (ABPM) and allergic fungal sinusitis (AFS), whether the fungus causes or 
sensitizes the asthma is unclear. (Methods) The bronchial provocation test using S. 
commune antigen was performed in two asthmatics who had demonstrated positive skin 
reaction to S. commune antigen, and low dose of itraconazole (50 mg/day) for 2 weeks 
was prescribed as an adjunctive therapy. The allergological features and clinical 
manifestations of them were herein evaluated and discussed. (Results) Case 1 was a 
71-year-old female. And case 2 was a 69-year-old male. Both patients demonstrated 
positive reaction to the inhalation test. A diagnosis of AFS or ABPM was excluded in 
both patients because of the lack of a history of pulmonary infiltrates, central 
bronchiectasis, a history of expectoration of brown plugs or flecks, or sinusoidal 
findings. Though the efficacy of itraconazole in our cases was unclear, the elevated titer 
of the specific IgG for S. commune in case 2 gradually decreased during the period of 
antifungal therapy. (Conclusions) The two patients described here were diagnosed to 
have bronchial asthma caused by S. commune; so-called Schizophillum asthma. S. 
commune may be a causative fungal antigen of bronchial asthma. 
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There has been increasing interest in the relationship between severe asthma and 
fungal sensitization [1-3]. Therefore, testing in adults with asthma that does not respond 
to first-line treatment should include not only such routine investigation as lung 
function, sinus CT scanning, sensitization to common inhalant allergens or evaluation of 
evidence for allergic bronchopulmonary aspergillosis (ABPA) [4], but should also 
include an evaluation for evidence of colonization with a range of fungi including 
Alternaria, Candida, and Trichophyton as well as Aspergillus species [5]. 
Recent research has focused on the possible role of basidiomycetous (BM) fungi as a 
fungal aeroallergen [6], and allergic fungal respiratory disease [7] caused by BM fungi 
have been increasingly reported [8-10]. Although it is well-known that Schizophyllum 
commune (S. commune), one of the BM fungi, causes mucoid impaction of bronchi 
(MIB) [11], allergic bronchopulmonary mycosis (ABPM) [12] and allergic fungal 
sinusitis (AFS) [13], it still remains unclear whether this fungus really causes or triggers 
asthma symptoms similar to Aspergillus species [14] or not. 
 This report describes two patients with bronchial asthma caused by S. commune; 
so-called Schizophillum asthma. Except for the criteria of the pulmonary involvement, 
such as central bronchiectasis and mucoid impaction, both cases met the criteria of 
ABPM caused by S. commune. Therefore, it was difficult to distinguish Schizophyllum 
asthma from eosinophilic bronchitis involved in ABPM caused by S. commune.  
This raises the question of whether the proposed Schizophyllum asthma is actually a 
new clinical entity similar to both Trichophyton asthma [15, 16] and Candida asthma 
[17], or instead is a precursor of ABPM caused by S. commune.  
 
Material and Method 
Preparation of the antigenic solution 
S. commune:  One liter of Sabouraud’s dextrose broth in 3 liter flasks was sterilized. 
Five milliliters of a S. commune spore suspension (105 spores per ml) in sterile 
physiological saline from 14 day-old Sabouraud’s dextrose agar culture were used to 
inoculate the flask. The flask was shaken at 25 °C at 150 rpm in a rotary shaker 
incubator for 14 days. Mycelia were separated by filtration and centrifuged. The 
supernatants were dialyzed against 5 mM ammonium bicarbonate and lyophilized.  
 
Allergological tests 
Intradermal skin test and serological test 
The antigenic solution (polysaccharide) was injected intradermally using a tuberculin 
syringe (0.02 mL, 1 mg/mL) to assess the skin response to the solution. The results of 
the immediate-type and the late-type responses were judged to be positive in a case of 
the longer axis of the flare beyond 10 mm at 15 minutes and at 8 hour after the injection, 
respectively. The Phadia (previously Pharmacia) CAP system was used to quantify 
specific IgG and IgE levels (Phadia Ltd, Uppsala, Sweden) [18]. A positive test was 
taken as a measurement > 2.00 (mgA / L) and > 0.35 (UA/mL), respectively. 
 
Lymphocyte stimulation test 
The lymphocyte stimulation test [19] was performed using the antigenic solution 
with the Lymphoprep system. The results were considered to be positive when the 
magnitude of the response to S. commune was beyond 200% in comparison to the 
controls using PHA. 
 
Bronchoprovocation test  
After obtaining informed consent, a 2 ml dose of culture-filtrate antigen solution at the 
concentration (maximum at 1 mg/mL), which was determined based on the threshold of 
the weakest positive immediate skin reaction, was inhaled by tidal mouth breathing 
from a Devilbiss 646 nebulizer (Devilbiss Co, Somerset, Pennsylvania, USA), which 
was operated by compressed air at a flow rate of 5 L/min. The responses were assessed 
to be positive when PaO2 significantly decreased (more than 20%), patients developed 
asthma attacks with 20% decrease in PEF and/ or FEV 1.0, laboratory findings such as 
WBC and CRP significantly elevated, and/or patients developed cough attacks with a 
significant increase in the cough reflex sensitivity to inhaled capsaicin, which was 
measured prior to and 24 hours after the provocation test.  
 
A statement of IRB approval  
This case study was approved by the institutional review boards (the IRB committee 
of Saiseikai Kanazawa Hospital; reference number 2009006) and informed consent 
was obtained from the two patients. 
 
Case report 1 
A 71-year-old female long-term asthmatic patient was admitted to the hospital on 
October 4, 2010 for the treatment of a chest discomfort and dyspnea. Her cough and 
wheezing developed in September 2010 and had not improved. She was a non-smoker. 
A physical examination revealed a body temperature of 36.8oC and a heart rate of 72 
beats per minute. Auscultation revealed wheezes and rhonchi. 
Laboratory tests revealed a white blood cell count of 8500 per µl with 0.7% 
eosinophils. C-reactive protein was present at 0.01 mg/dL. A radioimmunosorbent test 
revealed a normal level of IgE (35 U/mL), and the radioallergosorbent test for specific 
IgE antibodies against Aspergillus, Penicillium, Candida, Cladosporium, Alternaria and 
Trichophyton were all negative. A differential cell analysis of sputum was as follows: 
15% alveolar macrophages, 82% neutrophils, and 3% eosinophils. 
Chest radiographs and computed tomography of the chest and sinus taken upon 
admission showed normal findings. A pulmonary function test using the Collins DS 
system [20] revealed a FVC of 2.94 L (133.0% of predicted value), a FEV1 of 1.35 L 
(84.9% of predicted value), and an FEV1/FVC ratio of 45.9%. The bronchodilator 
therapy revealed slight increase in FEV1 values (from 1.35 to 1.37 L). 
The immediate (15 min) skin reaction (1 mg/ml) was 0 x 0/0 x 0 mm for 
Aspergillus, 4 x 4/0 x 0 mm for Alternaria, 5 x 5/0 x 0 mm for Candida, 4 x 4/0 x 0 mm 
for Bjerkandera adusta (B.adusta), and 10 x10/0 x 0 mm for S. commune.  The late 
skin reactions were positive for only S. commune (10 x 10/ 0 x 0 mm).  
Because she was suspected to be sensitized to S. commune, the closer 
examination was performed. Though the bronchoprovocation test using Aspergillus 
antigen was negative, the results of the bronchoprovocation test using S. commune at the 
concentration of 10-1mg/mL was graded as positive due to the development of a 
coughing symptom and significant decreases in PEF (from 200 to 130 L/min), 10 hrs 
after the inhalation challenging. These symptoms spontaneously disappeared next day 
(Table. 1a).  
She was treated with the leukotriene receptor antagonist montelukast sodium (10 
mg/day), theophylline (200 mg/day), transdermal tulobuterol patch (2 mg/day), inhaled 
budesonide/formoterol (2 puffs/day), and inhaled tiotropium bromide hydrate (18 
μg/day). She was treated with itraconazole (ITCZ) (50 mg/day) for 2 weeks as an 
adjunctive therapy. The score of the Asthma Control Test (ACT) showed a slight 
increase from 13 to 16 (Table.2).  
 
Case report 2 
 A 69-year-old male asthmatic patient was admitted to the hospital on August 24, 2010 
for closer examination of fungal sensitization of asthma. He was administrated 
montelukast sodium (10 mg/day), transdermal tulobuterol patch (2 mg/day) and inhaled 
beclomethasone dipropionate (400 μg/day) on a basis of a diagnosis of asthma for about 
5 years. He was suspected to be sensitized to S. commune because his intradermal skin 
test to this fungus revealed a strong positive finding (20 x 20/68 x 74 mm). He was a 
non-smoker. Physical examination revealed the following: his temperature was 36.2 oC, 
blood pressure 131/79 mmHg, and heart rate 68 beats per minute. Auscultation did not 
reveal any abnormalities except forced late expiratory wheezes. 
Laboratory studies showed a white blood cell count of 5,000 per µl with 2.0% 
eosinophils. No inflammatory reactions were observed as assessed by C-reactive protein 
level and erythrocyte sedimentation rate. Radioimmunosorbent tests revealed normal 
level of IgE (114 U/ml), and the results of radioallergosorbent test for specific IgE 
antibodies against Aspergillus was 0.57 (UA/mL), and negative for Penicillium, 
Candida, Cladosporium, Alternaria, house dust or mites. Differential cell analysis of 
sputum revealed eosinophilia (88% alveolar macrophages, 10% neutrophils, and 2% 
eosinophils). 
Chest radiographs and computed tomography of the chest and sinus taken upon 
admission showed normal findings. A pulmonary function test revealed a FVC of 3.02 
L (91.0% of predicted value), a FEV1 in 1 second of 1.73 L (70.3% of predicted value), 
and a FEV1/FVC ratio of 57.3%. The bronchodilator therapy revealed a small increase 
in the FEV1 value (from 1.73 to 1.84 L).  
The immediate (15 min) skin reaction was 9 x 8/40 x 40 mm for Aspergillus and 0 
x 0/4 x 4 mm for Alternaria and Candida. The result of prick test for S. commune (10-10 
mg/ml) examined before the intradermal skin test was 5x5/0x0 mm. Additional 
examinations of the immediate (15 min) skin reaction for S. commune produced the 
following findings: 8 x 6/28 x 22, 8 x 5/0 x 0, 5 x 5/0 x 0, 3 x 3/0 x 0, 4 x 4/0 x 0, 4 x 
4/0 x 0, and 5 x 5/0x 0 mm at concentrations of 2 x10-4, 10-4,10-5, 10-6, 10-7, 10-8, 10-9 
and 10-10 mg/ml, respectively. 
The bronchoprovocation test using Aspergillus antigen was negative; however, 
the test using S. commune antigen at the concentration of 10-4 mg/ml was graded as 
positive due to the development of a wheezing attack, decreases in PEF (from 440 to 
340 L/min) 3hr after the provocation. These symptoms spontaneously disappeared next 
day after the challenge without any additional therapy (Table. 1b). 
He was discharged on August 27 and treated with ITCZ (50 mg/day) for 2 
weeks as an adjunctive therapy. The FEV1 values showed a slight increase from 1.67 
to 1.75 L accompanied with decrease of the specific IgG for S. commune (from 8.10 
to 7.28 mg A/L; Table.2).  
 
Discussion 
It is important to elucidate the etiological agents and the exacerbating factors in 
allergic fungal respiratory diseases (AFRD) [7]. In particular, there has been increasing 
interest in the association between severe asthma and fungal sensitization [1-3]. 
Recently, it is stated in Global Initiative for Asthma (GINA) 2009 that describing 
patients as having allergic asthma is usually of little benefit, unless a single specific 
trigger agent can be identified [21]. However, different from occupational asthma, an 
environmental fungus cannot be the only etiological factor that causes asthma 
symptoms. Even if asthmatics have positive intradermal reaction against some fungus, it 
does not necessarily mean that the concern fungus is a causative antigen of the 
asthmatics. Therefore, the finding that the concern fungi can cause asthma symptoms is 
itself important. 
Because there was no history of pulmonary infiltrates and no history of any 
expectoration of either brown plugs or flecks, and because there was no central 
bronchiectasis and no sinusoidal findings, the two patients were diagnosed to have 
bronchial asthma caused by S. commune, which is so-called Schizophillum asthma, 
instead of being diagnosed to have AFS or ABPM due to S. commune. Subsequently, 
this report has proved that S. commune is an environmental factor which causes asthma 
symptoms.  
 We recently found that specific IgE for S. commune was negative in most of patients 
with MIB who were not sensitized by S. commune, and in a large number of patients 
with bronchial asthma who were sensitized to S. commune (Details of this report will be 
shown in another manuscript), it may be considered that the positive titer is one of 
reliable items for making a diagnosis of ABPM caused by S. commune. The positive 
results of the serum IgE and IgG to S. commune titer suggest that Case 2 may be a 
precursor of ABPM allergologically. 
 We have previously reported that the positive ratios for the immediate cutaneous 
reaction and the lymphocyte stimulation test to Bjerkandera adusta (B. adusta) were 
found to be significantly higher in the allergic fungal cough (AFC) sensitized to B. 
adusta group than in that non-sensitized group [22]. The lymphocyte response to S. 
commune may also play a part of important role in immunological systems in 
Schizophyllum asthma.(結果まちです)  
There is evidence of a close link between fungal sensitization and asthma severity 
[3]. Denning et al. reported that the results of a randomized controlled trial (FAST 
study) that showed a significant quality of life benefit, a fall in IgE, and a modest 
improvement in rhinitis and morning PEF, but not FEV1, after oral antifungal therapy in 
patients with severe asthma sensitized to one of several common fungi [23]. Gonzalez 
GM et al. reported that S. commune was susceptible in vitro to ITCZ, amphotericin B, 
and voriconazole, with MIC values of 0.06, 0.5, and 0.5 µg/ml, respectively [24]. 
Therefore, such antifungal therapy may have some advantages [9, 22, 25, and 26] in 
either reducing or eradicating such antigen exposure [23]. Though the efficacy of ITCZ 
(50 mg/day for 2 weeks) in our cases was unclear, the elevated titer of the specific IgG 
for S. commune in case 2 gradually decreased during the period of antifungal therapy. 
It is necessary to determine whether the quantity of the daily dose of ITCZ and the 
duration of the therapy are appropriate. The efficacy of antifungal drugs for this 
condition is worth being investigated also from another aspect such as the potential of 
preventing the development of ABPM. 
We have previously accomplished bronchoprovocation test using S. commune antigen 
for the definitive diagnosis of ABPM, the inhalation test was graded as positive due to 
the development of a coughing attack and a ticklish throat, significant decrease in PaO2, 
and increase in the serum CRP, but the patient did not experience asthma attack in the 
examination. Thus, even if there is some overlap between the eosinophilic bronchitis of 
Schizophyllum asthma and that of ABPM caused by S. commune, it is considered that 
Schizopyllum asthma is not always a precursor of ABPM.     
Both B. adusta and S. commune are BM fungi that colonize rotting wood and are 
distributed throughout the world. They are whitish in color when young and become 
darker shades of gray at maturity; B. adusta causes allergic fungal cough (“Yakeirotake 
cough” in Japanese) [27] but not bronchial asthma nor ABPM. The difference of the 
clinical manifestation (AFC, ABPM or asthma) evoked by such BM fungi may depend 
on the allergological characteristics of each fungus.  
 This report presented two patients with Schizophillum asthma (“Suehirotake 
asthma” in Japanese). The results of these cases suggest that S. commune is a potential 
causative fungal antigen of bronchial asthma similar to Trichophyton. Further studies 
are required to determine whether environmental fungi such as S. commune, which are 
easily deposited within the airway, may enhance the clinical symptoms of bronchial 
asthma. It is also important to follow such patients carefully to estimate whether the 















The authors wish to thank Dr. Masakatsu Seo (Seo Laboratory) for extending his 
help in the macroscopic identification of the fungal species, Dr. Kazuo Akiyama 
(Clinical Research Center for Allergy and Rheumatology, National Hospital 
Organization, Sagamihara National Hospital) for preparing the antigenic solution. 
This study was supported in part by a grant-in-aid for Scientific Research from the 
Ministry of Education, Culture, Sports Science and Technology - Japan (17607003). 
 
References  
1. Agarwal R, Gupta D. Severe asthma and fungi: current evidence. Med Mycol 2010 
(Epub ahead of print) 
2. Madani Y, Barlow A, Taher F. Severe asthma with fungal sensitization: a case 
report and review of literature. J.Asthma 2010; 47:2-6. 
3. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link 
between fungi and severe asthma: a summary of the evidence. Eur Respir J. 2006 Mar; 
27(3):615-626. 
4. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical 
and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. 
Ann Int Med 1977;86, 405-414. 
5. Platts-Mills TA, Woodfolk JA.Trichophyton asthma. Chest 2009;135:887-888. 
6. Helbling A, brander KA, Horner WE, Lehrer SB. Allergy to basidiomycetes. Chem 
Immunol. 2002;81:28-47. 
7. Ogawa H. The importance of the environmental fungi in the allergic lower respiratory 
disease. The allergy in practice (in Japanese) 2010;97:7-23. 
8. Ogawa H, Fujimura M, Takeuchi Y, Makimura K. A case of sinobronchial allergic 
mycosis; Possibility of basidiomycetous fungi as a causative antigen. Intern Med. 
2011;50(1):59-62. Epub 2011 Jan 1. 
9. Ogawa H, Fujimura M, Takeuchi Y, Makimura K. Efficacy of itraconazole in the 
treatment of patients with chronic cough whose sputa yield basidiomycetous fungi 
—Fungus-associated chronic cough (FACC). J Asthma 2009;46:407-411. 
10. Ogawa H, Fujimura M, Takeuchi Y, Makimura K. The importance of 
basidiomycetous fungi cultured from the sputum of chronic idiopathic cough—A study 
to determine the existence of recognizable clinical patterns to distinguish CIC from 
non-CIC. Resp Med 2009;103;1492-1497. 
11. Amitani R, Nishimura K, Niimi A, Kobayashi H, Nawada R, Murayama T, et al. 
Bronchial mucoid impaction due to the monokaryotic mycelium of Schizophyllum 
commune. Clin infect Dis. 1996;22:146-148. 
12. Kamei K, Unno H, Nagao K, Kuriyama T, Nishimura K, Miyaji M. Allergic 
bronchopulomonary mycosis caused by the basidiomycetous fungus Schizophyllum 
commune. Clin Infect Dis 1994;18:305-309. 
13. Clark S, Campbell CK, Sandison A, Choa DI. Schizophillum commune: an unusual 
isolate from a patient with allergic fungal sinusitis. J infect. 1996;32:145-150. 
14. Shah A, Panchal N, Agarwal AK. Concomitant allergic bronchopulmonary 
aspergillosis and allergic Aspergillus sinusitis: a review of an uncommon association. 
Clin Exp Allergy 2001;31:1896-1905. 
15. Ward GW Jr, Karlsson G, Rose G, Platts-Mills TA. Trichophyton asthma: 
sensitisation of bronchi and upper airways to dermatophyte antigen. Lancet 1989; 
1(8643): 859-862. 
16.  Matsuoka H, Niimi A, Matsumoto H, Ueda T, Takemura M, Yamaguchi M, et al. 
Specific IgE response to trichophyton and asthma severity. Chest 2009;135:898-903 
17. Keeney EL. Candida asthma. Ann Intern Med 1951;34:223-226. 
18. Hoeyveld EV, Dupont L, Bossuyt X. Quantification of IgG antibodies to 
Aspergillus fumigatus and pigeon antigens by immunoCAP technology: An 
alternative to the precipitation technique? Clinical Chemistry 2006;52:1785-1793. 
19. Warrington RJ, Tse KS, Gorski BA, et al; Evaluation of isoniazid-associated 
hepatitis by immunological tests. Clin Exp Immunol 1981;32:97-104. 
20. American Thoracic Society: Standardization of spirometry-1987 update. Am Rev 
Respir Dis 1987; 136:1285-1298. 
21. Global Initiative for asthma. Global strategy for asthma management and 
prevention. Updated 2009. Available from:www.ginasthma.com. 
22. Ogawa H, Fujimura M, Takeuchi Y, Makimura K. Is Bjerkandera adusta 
important to fungus-associated chronic cough (FACC) as an allergen? Eight cases’ 
report. J asthma 2009.46:849-855. 
23. Denning DW, O'Driscoll BR, Powell G, Chew F, Atherton GT, Vyas A et al.  
Randomized controlled trial of oral antifungal treatment for severe asthma with fungal 
sensitization. Am J Respir Crit Care Med 2009;179:11-18. 
24. Gonzalez GM, Sutton DA, Thompson E, Tijerina R, Rinaldi MG. In vitro activities 
of approved and investigational antifungal agents against 44 clinical isolates of 
basidiomycetous fungi. Antimicrob Agents Chemother 2001;45:633-635. 
25. Ogawa H, Fujimura M. Tofuku Y. Two cases of atopic cough successfully treated by 
oral cleansing with amphotericin B. Basidiomycetes detected from pharyngeal swab. 
Allergology International 2004;53:193–196. 
26. Ogawa H, Fujimura M, Tofuku Y. Treatment of atopic cough caused by 
Basidiomycetes antigen with low dose Itraconazol. Lung 2004;182:279-284. 
 
Tables 
Table 1a, 1b   Results of bronchoprovocation test  





Case 1 run in pre-itraconazole post-itraconazole
ACT 19 13 16
FEV1 (l) 1.34 1.27 1.3
MMF (l/s) 0.37 0.3 0.27
Specific IgG- for S. commune (mgA/L < 2
Specific IgE- for S. commune (mgA/L < 0.35
Case 2 run in pre-itraconazole post-itraconazole
ACT 19 22 23
FEV1 (l) 1.82 1.67 1.75
MMF (l/s) 0.56 0.56 0.4
Specific IgG- for S. commune (mgA/L 9.57 8.1 7.28
Specific IgE- for S. commune (mgA/L 2.8
